✦ LIBER ✦

Pathogen safety profile of a new 10% liquid, triple virus reduced intravenous immune globulin product, new generation IGIV (NG IGIV)—Further studies

✍ Scribed by Kreil, T.R.; Poelsler, G.; Bailey, A.C.; Teschner, W.; Schwarz, H.P.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Development of a new 10% liquid, triple

✍ KREIL, T 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 25 KB

Efficacy, safety and tolerability of a n

✍ Church, J.A.; Leibl, H.; Stein, M.R.; Melamed, I.R.; Rubinstein, A.; Schneider, 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 26 KB

Preclinical characterization of a new li

✍ TESCHNER, W 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 26 KB